Revive Therapeutics Ltd - RVVTF stock

From OTC Wiki


Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of therapies for rare medical conditions and contagious illnesses. The company provides a pharmaceutical portfolio centered around cannabinoids, with a particular focus on addressing rare inflammatory diseases. They are currently working on several projects, including Bucillamine, which is in Phase 3 clinical trials for the treatment of infectious diseases such as influenza and COVID-19; Psilocybin, in Phase 1 clinical trials for addressing methamphetamine use disorder; Psilocin, aimed at treating conditions like depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other disorders; and cannabidiol, intended for the treatment of autoimmune hepatitis and organ transplantation-related ischemia and reperfusion injury. The company is headquartered in Toronto, Canada.[1]

The stock began trading on the OTCQC market on June 28, 2021 under the symbol RVVTF.[2]


Revive Therapeutics Ltd has collaborated with several institutions to propel research on specific diseases. These include North Carolina State University[3], the University of California[4], and the University of Health Services Antigua.[5]

Acquisitions and Mergers[edit]

In July 2013, Revive Therapeutics entered into a letter of intent to acquire Mercury Capital II Limited(TSXV:MFF.P) in a reverse merger transaction. The merger resulted in Mercury advancing 12.9 million of its shares to shareholders of Revive Therapeutics.[6]

On March 5, 2020, the company announced the completion of the acquisition of all the issued and outstanding shares of Psilocin Pharma Corp. Psilocin is a psychedelic Science company that dedicates research and development of Psilocybin-based therapeutics for significant medical needs. Revive banked all the issued and outstanding securities, an aggregate of 55 million common shares at approximately $2.7 million.[7]

On February 17, 2021, Revive gladly announced their asset purchase agreement with Newscope Capital Corporation (“Newscope”) (CSE: PHRM) (OTCQB: PHRRF) to obtain full rights of PharmaTher Inc.’s (“PharmaTher”) intellectual property (the “Acquired Assets”) of psilocybin (the “Acquisition”). The purchase saw Revive spend $10 million on aggregate. Acquired assets included all intellectual and work property from pre-clinical research events from the National Health Research Institutes (NHRI) and vital provisional patent applications with the U.S. Patent and Trademark Office.[8]


Financial performance for Revive Therapeutics:[9]

Year Ending Revenue Net Income Earnings per Share Total Liabilities Cash Balance
6/30/2023 $0 ($13,804,000) ($0.05) $3,459,000 $3,035,000
6/30/2022 $0 ($16,247,000) ($0.06) $807,000 $13,405,000
6/30/2021 $0 ($3,951,000) ($0.04) $610,000 $1,014,000
6/30/2020 $0 ($1,028,000) ($0.02) $246,000 $363,000
Related pages


The page is authored by: Wisdom Tree, Crescendo